Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | EED | O75530 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17827656 | 0.81 | CHKA (0.50) | CHKAADRB2NCF1PLD1MAPT | |
| SCHEMBL27703385 | 0.80 | CYP1A2 (0.49) | MAPTMAPK1ALDH1A1TRPV1 | |
| SCHEMBL20406252 | 0.80 | CYP1A2 (0.53) | MAPTMAPK1ALDH1A1TRPV1 | |
| SCHEMBL14334678 | 0.80 | GRIN2D (0.51) | CHKAADRB2NCF1PLD1MAPT | |
| SCHEMBL1432779 | 0.79 | CYP1A2 (0.56) | LMNAMAPK1ALDH1A1 | |
| SCHEMBL10112808 | 0.79 | HRH4 (0.53) | — | |
| SCHEMBL14376531 | 0.76 | CHKA (0.44) | CHKAADRB2NCF1PLD1MAPT | |
| SCHEMBL2415357 | 0.76 | EPHX2 (0.59) | PLD1ALDH1A1HTR2A | |
| SCHEMBL28112415 | 0.75 | CHKA (0.80) | CHKAADRB2NCF1PLD1MAPT | |
| SCHEMBL7236851 | 0.75 | KMT2A (0.62) | CHKAMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-12 | — | — | US | disclosed |
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-12 | — | — | US | disclosed |
| US-20160168124-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
| US-20160168124-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, PIR | CHKA 4208/4885ADRB2 2935/4885NCF1 2165/4885 |
| US-20160168124-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, PIR | CHKA 4208/4885ADRB2 2935/4885NCF1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.